Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Evaluate Vaxart Human Papillomavirus (HPV) Vaccine for the Treatment of Human Papillomavirus (HPV)–Associated Cancer and Dysplasia

Trial Profile

A Clinical Trial to Evaluate Vaxart Human Papillomavirus (HPV) Vaccine for the Treatment of Human Papillomavirus (HPV)–Associated Cancer and Dysplasia

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Human papillomavirus vaccine (Primary)
  • Indications Cancer; Cervical cancer; Cervical dysplasia; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Vaxart
  • Most Recent Events

    • 10 Dec 2018 New trial record
    • 09 Nov 2018 According to a Vaxart media release, the company is advancing its first therapeutic vaccine (Vaxart HPV vaccine) for the treatment of human papillomavirus (HPV)-associated cancer and dysplasia, and is on track to file an IND for the HPV vaccine in 2019.Preparations to advance this program into the clinic in 2019 are underway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top